KPV vs Liraglutide
Side-by-side comparison of key properties, dosing, and research.
Immune SupportRecovery & Repair
KPVGLP-1 / Weight Loss AgonistsFat Loss & Metabolic
Liraglutide- Summary
- KPV is a naturally occurring anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It powerfully suppresses intestinal and systemic inflammation via melanocortin receptors, making it valuable for IBD, gut healing, and wound repair.
- Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
- Half-Life
- Short half-life (~15–30 minutes), but effects persist longer due to receptor-level anti-inflammatory cascades
- ~13 hours (once-daily dosing)
- Admin Route
- Oral, SubQ, Topical
- SubQ
- Research
- —
- —
- Typical Dose
- 500 mcg – 1 mg
- Start 0.6 mg, titrate to 3 mg
- Frequency
- Once to twice daily
- Once daily
- Key Benefits
- Reduces intestinal inflammation (IBD, Crohn's, colitis)
- Promotes gut mucosal healing and barrier integrity
- Accelerates wound healing topically
- Suppresses systemic inflammatory cytokines
- Antimicrobial properties against pathogens
- Reduces neuroinflammation when administered systemically
- May improve symptoms of inflammatory skin conditions
- Promotes weight loss (5–10% average)
- Reduces appetite and caloric intake
- Improves blood glucose control (HbA1c reduction)
- Reduces cardiovascular events in T2DM (LEADER trial)
- Slows gastric emptying
- FDA-approved for T2DM and chronic weight management
- Cardioprotective effects shown in clinical trials
- May improve fatty liver (NAFLD/NASH)
- Side Effects
- Generally very well tolerated
- Mild injection site reactions (SC)
- Rare: transient flushing
- Nausea (very common, especially initially)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- +5 more
- Stacks With
- —
- —